CPT® Code 91307

Deleted

1. Indications

The vaccine coded under CPT® 91307 is indicated for the prevention of coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is specifically designed for use in pediatric populations, particularly children aged 5 to 11 years, including those who are immunocompromised and may require a third dose for enhanced protection.

• COVID-19 Prevention The vaccine is intended to provide immunity against COVID-19, reducing the risk of severe illness, hospitalization, and death associated with the disease.
• Pediatric Use This vaccine is specifically formulated for children aged 5-11 years, addressing the unique dosing requirements for this age group.
• Immunocompromised Patients A third dose is available for children who are immunocompromised, ensuring they receive adequate protection against the virus.

2. Procedure

The administration of the vaccine involves several key procedural steps to ensure safety and efficacy. First, the vaccine must be prepared by diluting the concentrated vaccine with preservative-free normal saline to achieve the appropriate dosage of 10 mcg per 0.2 mL. This preparation is crucial as it ensures that the vaccine is safe for pediatric use and meets the specific dosing requirements for children. Next, the healthcare provider must verify the patient's eligibility for vaccination, including confirming the patient's age and any relevant medical history, particularly for immunocompromised individuals who may require a third dose. Once the vaccine is prepared and the patient is deemed eligible, the healthcare provider will administer the vaccine via intramuscular injection, typically into the deltoid muscle of the upper arm. It is essential to follow proper injection techniques to minimize discomfort and ensure the vaccine is delivered effectively. After the injection, the patient should be monitored for a brief period to observe for any immediate adverse reactions, which is a standard practice for vaccine administration. This monitoring period allows healthcare providers to respond promptly to any potential allergic reactions or side effects.

• Step 1: Vaccine Preparation Dilute the concentrated vaccine with preservative-free normal saline to achieve a dosage of 10 mcg per 0.2 mL.
• Step 2: Patient Verification Confirm the patient's eligibility for vaccination, including age and medical history.
• Step 3: Vaccine Administration Administer the vaccine intramuscularly into the deltoid muscle, following proper injection techniques.
• Step 4: Post-Injection Monitoring Monitor the patient for any immediate adverse reactions following the vaccination.

3. Post-Procedure

After the administration of the vaccine, patients are typically advised to remain in the healthcare setting for a short observation period to monitor for any immediate side effects or allergic reactions. Common post-vaccination reactions may include mild pain at the injection site, fatigue, headache, muscle pain, chills, fever, or joint pain, which are generally self-limiting and resolve within a few days. Patients and caregivers should be provided with information regarding potential side effects and the importance of completing the vaccination series, if applicable. Additionally, they should be informed about the need for follow-up appointments for subsequent doses, especially for those receiving the two-dose series or the third dose for immunocompromised individuals. It is also essential to encourage patients to report any unusual or severe reactions to their healthcare provider, ensuring that any adverse events are documented and addressed appropriately. Overall, the post-procedure care focuses on monitoring for reactions and ensuring the patient understands the importance of follow-up care and vaccination completion.